{"entity":{"id":"nct06730750","kind":"trial","name":"A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Bevacizumab in advanced solid tumours, run by Bristol-Myers Squibb, active and no longer recruiting.","summary":"A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06730750 by Bristol-Myers Squibb, with 360 participants enrolled, started 2025-02-12 and due to reach its primary completion in 2026-09-05. Interventions recorded: BMS-986490 and Bevacizumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06730750","url":"https://clinicaltrials.gov/study/NCT06730750"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["antiangiogenic","monoclonal-antibody"],"targets":[],"drugs":["bevacizumab"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06730750","phase":"1/2","setting":"A Phase 1/2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors","sponsor":"Bristol-Myers Squibb","participation":[{"nct":"NCT06730750","source":"https://clinicaltrials.gov/study/NCT06730750","fetchedAt":"2026-10-07T16:54:58.037Z","studySha256":"cc51fb9f2f83012c10ec25d3ee119862f8598ae9939b5b68161257faebb43adb","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-09-01","leadSponsor":"Bristol-Myers Squibb","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":360,"enrolmentType":"ESTIMATED","siteCount":6,"recruitingSiteCount":0,"countries":["Australia","Canada","United States"]}],"started":"2025-02-12","startedType":"actual","enrolled":360,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06730750/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}